Skip to search formSkip to main contentSkip to account menu

Aggressive Non-Hodgkin Lymphoma

Known as: Aggressive Non-Hodgkin's Lymphoma, Non-Hodgkin lymphoma, aggressive, NOS, aggressive lymphoma 
A non-Hodgkin lymphoma with an aggressive clinical course. Representative examples include Burkitt lymphoma, mantle cell lymphoma, and… 
National Institutes of Health

Related topics

Related topics

11 relations
Atypical lymphocyteHematopoietic and Lymphoid CellHematopoietic and Lymphoid TissueLymphatic System

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Development and measurement of guideline-based indicators for patients with non-Hodgkin's lymphoma.
PURPOSE Patients with cancer are not always treated according to available guidelines. Factors such as age and comorbidities are… 
Highly Cited
2008
Highly Cited
2008
Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support
2007
2007
Cyclooxygenase-2 expression in non-Hodgkin's lymphomas
Cyclooxygenase 2 (Cox-2) is a key enzyme in prostaglandin synthesis and it has an important role in the pathogenesis of various… 
Highly Cited
2006
Highly Cited
2006
The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma
Purpose: Methotrexate is known to synergize with cytarabine [1-β-d-arabinofuranosylcytosine (ara-C)] in a schedule-dependent… 
Review
2003
Review
2003
Treatment and survival of 38 female breast lymphomas: a population-based study with clinical and pathological reviews
Breast lymphomas are rare and consensus about their treatment is lacking. A population-based study of 38 breast lymphomas… 
Highly Cited
2003
Highly Cited
2003
Upregulation of galectin-7 in murine lymphoma cells is associated with progression toward an aggressive phenotype
We have previously shown that ICAM-1-deficient mice were resistant to lymphoma dissemination of intravenously injected 164T2… 
Highly Cited
2001
Highly Cited
2001
Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma.
Advances in chemotherapy have led to a favorable long-term prognosis in approximately 50% of patients with aggressive non-Hodgkin… 
1999
1999
Gelatinase B (MMP‐9), but not its inhibitor (TIMP‐1), dictates the growth rate of experimental thymic lymphoma
Dysregulation of metalloproteinase production at tumor sites contributes to the modification of local stromal tissue necessary… 
Highly Cited
1993
Highly Cited
1993
Mutation and protein expression of p53 in acquired immunodeficiency syndrome-related lymphomas.
p53 mutations are found in a variety of neoplasia. B-immunoblastic lymphoma (BIBL) is a rapidly progressive, aggressive lymphoma… 
Highly Cited
1985
Highly Cited
1985
Cytogenetic studies in human T-cell lymphoma virus (HTLV)-positive leukemia-lymphoma in the United States.
Cytogenetic studies were conducted on fresh and cultured cells from 11 patients with human T-cell leukemia virus-associated adult… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)